134 related articles for article (PubMed ID: 36511830)
21. Testing mutual exclusivity of ETS rearranged prostate cancer.
Svensson MA; LaFargue CJ; MacDonald TY; Pflueger D; Kitabayashi N; Santa-Cruz AM; Garsha KE; Sathyanarayana UG; Riley JP; Yun CS; Nagy D; Kosmeder JW; Pestano GA; Tewari AK; Demichelis F; Rubin MA
Lab Invest; 2011 Mar; 91(3):404-12. PubMed ID: 20975660
[TBL] [Abstract][Full Text] [Related]
22. ETS rearrangements in prostate cancer.
Rubin MA
Asian J Androl; 2012 May; 14(3):393-9. PubMed ID: 22504874
[TBL] [Abstract][Full Text] [Related]
23. The prognostic and predictive value of TMPRSS2-ERG gene fusion and ERG protein expression in prostate cancer biopsies.
Berg KD
Dan Med J; 2016 Dec; 63(12):. PubMed ID: 27910803
[TBL] [Abstract][Full Text] [Related]
24. Modulation of androgen receptor DNA binding activity through direct interaction with the ETS transcription factor ERG.
Wasmuth EV; Hoover EA; Antar A; Klinge S; Chen Y; Sawyers CL
Proc Natl Acad Sci U S A; 2020 Apr; 117(15):8584-8592. PubMed ID: 32220959
[TBL] [Abstract][Full Text] [Related]
25. The peripheral zone of the prostate is more prone to tumor development than the transitional zone: is the ETS family the key?
Adler D; Lindstrot A; Ellinger J; Rogenhofer S; Buettner R; Perner S; Wernert N
Mol Med Rep; 2012 Feb; 5(2):313-6. PubMed ID: 22038307
[TBL] [Abstract][Full Text] [Related]
26. Molecular profiling of ETS and non-ETS aberrations in prostate cancer patients from northern India.
Ateeq B; Kunju LP; Carskadon SL; Pandey SK; Singh G; Pradeep I; Tandon V; Singhai A; Goel A; Amit S; Agarwal A; Dinda AK; Seth A; Tsodikov A; Chinnaiyan AM; Palanisamy N
Prostate; 2015 Jul; 75(10):1051-62. PubMed ID: 25809148
[TBL] [Abstract][Full Text] [Related]
27. SLC45A3-ELK4 is a novel and frequent erythroblast transformation-specific fusion transcript in prostate cancer.
Rickman DS; Pflueger D; Moss B; VanDoren VE; Chen CX; de la Taille A; Kuefer R; Tewari AK; Setlur SR; Demichelis F; Rubin MA
Cancer Res; 2009 Apr; 69(7):2734-8. PubMed ID: 19293179
[TBL] [Abstract][Full Text] [Related]
28. Novel 5' fusion partners of ETV1 and ETV4 in prostate cancer.
Barros-Silva JD; Paulo P; Bakken AC; Cerveira N; Løvf M; Henrique R; Jerónimo C; Lothe RA; Skotheim RI; Teixeira MR
Neoplasia; 2013 Jul; 15(7):720-6. PubMed ID: 23814484
[TBL] [Abstract][Full Text] [Related]
29. Hormone-sensitive prostate cancer: a case of ETS gene fusion heterogeneity.
Attard G; Jameson C; Moreira J; Flohr P; Parker C; Dearnaley D; Cooper CS; de Bono JS
J Clin Pathol; 2009 Apr; 62(4):373-6. PubMed ID: 19066166
[TBL] [Abstract][Full Text] [Related]
30. Targeted radiosensitization of ETS fusion-positive prostate cancer through PARP1 inhibition.
Han S; Brenner JC; Sabolch A; Jackson W; Speers C; Wilder-Romans K; Knudsen KE; Lawrence TS; Chinnaiyan AM; Feng FY
Neoplasia; 2013 Oct; 15(10):1207-17. PubMed ID: 24204199
[TBL] [Abstract][Full Text] [Related]
31. Common gene rearrangements in prostate cancer.
Rubin MA; Maher CA; Chinnaiyan AM
J Clin Oncol; 2011 Sep; 29(27):3659-68. PubMed ID: 21859993
[TBL] [Abstract][Full Text] [Related]
32. Suppression of CHK1 by ETS Family Members Promotes DNA Damage Response Bypass and Tumorigenesis.
Lunardi A; Varmeh S; Chen M; Taulli R; Guarnerio J; Ala U; Seitzer N; Ishikawa T; Carver BS; Hobbs RM; Quarantotti V; Ng C; Berger AH; Nardella C; Poliseno L; Montironi R; Castillo-Martin M; Cordon-Cardo C; Signoretti S; Pandolfi PP
Cancer Discov; 2015 May; 5(5):550-63. PubMed ID: 25653093
[TBL] [Abstract][Full Text] [Related]
33. ETS gene fusions in prostate cancer.
Clark JP; Cooper CS
Nat Rev Urol; 2009 Aug; 6(8):429-39. PubMed ID: 19657377
[TBL] [Abstract][Full Text] [Related]
34. A small molecule inhibitor of ETV1, YK-4-279, prevents prostate cancer growth and metastasis in a mouse xenograft model.
Rahim S; Minas T; Hong SH; Justvig S; Çelik H; Kont YS; Han J; Kallarakal AT; Kong Y; Rudek MA; Brown ML; Kallakury B; Toretsky JA; Üren A
PLoS One; 2014; 9(12):e114260. PubMed ID: 25479232
[TBL] [Abstract][Full Text] [Related]
35. Truncated ERG proteins affect the aggressiveness of prostate cancer.
Wu F; Ding S; Lu J
Med Hypotheses; 2013 Apr; 80(4):490-3. PubMed ID: 23357671
[TBL] [Abstract][Full Text] [Related]
36. Distinct classes of chromosomal rearrangements create oncogenic ETS gene fusions in prostate cancer.
Tomlins SA; Laxman B; Dhanasekaran SM; Helgeson BE; Cao X; Morris DS; Menon A; Jing X; Cao Q; Han B; Yu J; Wang L; Montie JE; Rubin MA; Pienta KJ; Roulston D; Shah RB; Varambally S; Mehra R; Chinnaiyan AM
Nature; 2007 Aug; 448(7153):595-9. PubMed ID: 17671502
[TBL] [Abstract][Full Text] [Related]
37. Retention of Interstitial Genes between
Murphy SJ; Kosari F; Karnes RJ; Nasir A; Johnson SH; Gaitatzes AG; Smadbeck JB; Rangel LJ; Vasmatzis G; Cheville JC
Cancer Res; 2017 Nov; 77(22):6157-6167. PubMed ID: 29127096
[No Abstract] [Full Text] [Related]
38. Characterization of ETS gene aberrations in select histologic variants of prostate carcinoma.
Han B; Mehra R; Suleman K; Tomlins SA; Wang L; Singhal N; Linetzky KA; Palanisamy N; Zhou M; Chinnaiyan AM; Shah RB
Mod Pathol; 2009 Sep; 22(9):1176-85. PubMed ID: 19465903
[TBL] [Abstract][Full Text] [Related]
39. Intratumoral androgen levels are linked to TMPRSS2-ERG fusion in prostate cancer.
Knuuttila M; Mehmood A; Mäki-Jouppila J; Ryberg H; Taimen P; Knaapila J; Ettala O; Boström PJ; Ohlsson C; Venäläinen MS; Laiho A; Elo LL; Sipilä P; Mäkelä SI; Poutanen M
Endocr Relat Cancer; 2018 Sep; 25(9):807-819. PubMed ID: 29773553
[TBL] [Abstract][Full Text] [Related]
40. ETS factors reprogram the androgen receptor cistrome and prime prostate tumorigenesis in response to PTEN loss.
Chen Y; Chi P; Rockowitz S; Iaquinta PJ; Shamu T; Shukla S; Gao D; Sirota I; Carver BS; Wongvipat J; Scher HI; Zheng D; Sawyers CL
Nat Med; 2013 Aug; 19(8):1023-9. PubMed ID: 23817021
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]